Elevated Fasting Insulin Is Associated With Cardiovascular and Metabolic Risk in Women With Polycystic Ovary Syndrome
May 2019
in “
Diabetes and Metabolic Syndrome: Clinical Research and Reviews
”
alopecia acne amenorrhea acanthosis nigricans obesity hyperandrogenism polycystic ovary syndrome PCOS fasting insulin BMI WHR FAI LH:FSH ratio HOMA QUICKI HOMA-IR WHtR LAP hair loss insulin resistance body mass index waist-hip ratio free androgen index homeostatic model assessment quantitative insulin sensitivity check index waist-height ratio lipid accumulation product
Studysummary This study found that fasting insulin levels are associated with increased cardiovascular and metabolic risk factors in women with polycystic ovary syndrome. Our plain-language summary of this paper — not a Tressless recommendation.
The study, involving 349 women (249 with PCOS and 100 healthy controls), found that elevated fasting insulin levels in women with PCOS were significantly associated with a range of cardiovascular and metabolic risk factors. Women with PCOS had higher fasting insulin, BMI, WHR, FAI, LH:FSH ratio, HOMA, and QUICKI compared to controls. Higher fasting insulin levels in PCOS patients were correlated with increased BMI, BAI, LAP, HOMA-IR, QUICKI, and FAI. The study also categorized PCOS patients based on fasting insulin levels and found that those with higher levels had a greater prevalence of acne, alopecia, amenorrhea, acanthosis nigricans, and obesity, as well as higher cardiovascular-metabolic risk factors like BMI, WHtR, HOMA IR, FAI, and LAP. The conclusion was that fasting insulin is a key determinant in the pathogenesis of obesity and hyperandrogenism in PCOS and is linked to an increased risk of cardiovascular and metabolic disorders.
